Reports
Global Liver Cancer Therapeutics Market Share, Size, Trends, Growth, Analysis, Forecast: By Cancer Type: Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Others; By Therapy Type: Ablation Therapy, Others; By Route of Administration; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2023-2031
Global Liver Cancer Therapeutics Market Outlook
The global liver cancer therapeutics market size attained a value of USD 2.09 billion in 2022, driven by the rising prevalence of liver cancer and the growing demand for effective treatment options across the globe. The market is anticipated to grow at a CAGR of 19.85% during the forecast period of 2023-2031 to reach a value of USD 10.68 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Liver Cancer Therapeutics Market Trends
Cancer is a life-threatening disease where the cells of a part of our body go out of control and starts growing rapidly. This disease, when effects and starts growing in the liver, is known as liver cancer or hepatic cancer. Although early signs of liver cancer are usually non-existent, they may include unconditional weight loss, appetite loss, upper abdominal pain, nausea, and vomiting, abdominal swelling, jaundice, general weakness and fatigue.
- The rising prevalence of liver cancer diseases is a major factor propelling market growth. People around the world are increasingly adopting a sedentary and unhealthy lifestyle, with increased consumption of alcohol and tobacco. These are very injurious for the liver and are the primary factor to aid liver cancer therapeutics market development.
- Market players are developing a sturdy drug pipeline that can aid cancer research and development. This will help in the development of new treatments with combination therapy that can provide enhanced treatment to the patients.
- Market players and institutions are increasingly engaging in research and development activities to develop novel medicines and improve the treatment of cancer through therapeutic drugs, which can extend the patients' lifespan. The availability of improved therapeutic options can significantly help in market expansion.
Global Liver Cancer Therapeutics Market Analysis
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the market can be segmented into hepatocellular carcinoma, cholangio carcinoma, and hepatoblastoma, among others. Based on the therapy types, it can be bifurcated into ablation therapy, embolization therapy, radiation therapy, targeted therapy, immunotherapy, and chemotherapy. Based on the route of administration, the market for therapeutics includes oral and intravenous administration.
Based on distribution channels, the market for cancer therapeutics can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The regional markets for the liver cancer therapeutics market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.
- Bayer AG
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Exelixis, Inc.
- Merck & Co., Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Others
Types of Therapies in the Market for Cancer Treatment
The market for liver cancer therapeutics, based on therapy types, can be divided into ablation therapy, embolization therapy, radiation therapy, targeted therapy, immunotherapy, and chemotherapy.
Among the various types of therapies, targeted therapy is expected to cover a major portion of the market owing to the increasing demand for targeted therapy due to its various advantages. Targeted therapies are utilised to directly target tumour cells while eliminating the chances of acquiring side effects on the surrounding normal cells. The increasing utilisation of targeted therapy can be a major driving factor for the segment and market value.
Various Routes of Administration for Liver Cancer Therapeutics
Based on the route of administration, the market can be divided into oral and intravenous administration. The intravenous route is the most widely by healthcare professionals as a method of administration for cancer therapy methods such as chemotherapy.
Healthcare professionals utilise this route of administration to administer multiple doses of medication or give medicated infusions. This route eliminates the need to inject a needle or tool multiple times to administer the same medicine and allows the medication to directly reach blood circulation.
Oral administration is growing in demand due to it being a non-invasive method of administration. This mode of administration provides multiple benefits including patient comfort, cost-effectiveness, and easy large-scale manufacturing of the medication. The increasing patient preference for oral administration can prople market growth
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
Bayer AG, founded in 1863, and headquartered in Leverkusen, Germany, is a multinational pharmaceutical and biotechnology company. It is one of the world’s largest pharmaceutical companies with a speciality in various fields including pharmaceuticals, agricultural chemicals, seeds and biotechnology products, life sciences, and consumer health. The products developed by the company are applied to tackle some of the biggest challenges including global population growth, an ageing society, and to create sustainability.
Pfizer Inc. is an American pharmaceutical and biotechnology company. The company is headquartered in New York, United States, and it has been operating in the industry since 1849. The company works with an aim to introduce treatment solutions in the healthcare sector to create a healthier world. The company has expertise in utilising the science and global resources to improve healthcare around the world. The company is actively providing safe and effective medicines and healthcare services to underserved groups of people.
Bristol Myers Squibb Company is a multinational pharmaceutical company, headquartered in New York City, United States. The company was established in the year 1887 and has been operating in the field of biotechnology, pharmaceuticals, healthcare, and research and development, among others, to become one of the leading companies in the world.
The company has made multiple advancements in various medical fields such as oncology, haematology, immunology, and cardiovascular disease. Through their diverse array of products and innovative platforms, the company can assist patients in receiving better therapy at any stage of life.
Other market players include Exelixis, Inc., Merck & Co., Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd, among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Cancer Type |
|
| Breakup by Therapy Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Liver Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Liver Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Liver Cancer Epidemiology (2016-2031)
5.3 Europe Liver Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Liver Cancer Epidemiology (2016-2031)
5.5 Latin America Liver Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Liver Cancer Epidemiology (2016-2031)
6 Global Liver Cancer Therapeutics Market Overview
6.1 Global Liver Cancer Therapeutics Market Historical Value (2016-2022)
6.2 Global Liver Cancer Therapeutics Market Forecast Value (2023-2031)
7 Global Liver Cancer Therapeutics Market Landscape
7.1 Liver Cancer Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Liver Cancer Therapeutics: Product Landscape
7.2.1 Analysis by Cancer Type
7.2.2 Analysis by Therapy Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by Distribution Channel
7.2.5 Analysis by End User
8 Liver Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Liver Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Liver Cancer Therapeutics Market Segmentation
11.1 Global Liver Cancer Therapeutics Market by Cancer Type
11.1.1 Market Overview
11.1.2 Hepatocellular Carcinoma
11.1.3 Cholangio Carcinoma
11.1.4 Hepatoblastoma
11.1.5 Others
11.2 Global Liver Cancer Therapeutics Market by Therapy Type
11.2.1 Market Overview
11.2.2 Ablation Therapy
11.2.3 Embolization Therapy
11.2.4 Radiation Therapy
11.2.5 Targeted Therapy
11.2.6 Immunotherapy
11.2.7 Chemotherapy
11.3 Global Liver Cancer Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Intravenous
11.4 Global Liver Cancer Therapeutics Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacies
11.4.3 Retail Pharmacies
11.4.4 Online Pharmacies
11.5 Global Liver Cancer Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Clinics
11.5.4 Research and Academic Laboratories
11.5.5 Others
11.6 Global Liver Cancer Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Liver Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Liver Cancer Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Liver Cancer Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Liver Cancer Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Liver Cancer Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Bristol-Myers Squibb Company
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Eisai Co.,Ltd.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Exelixis Inc
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Merck & Co. Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Bayer AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Eli Lilly and Company
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 F. Hoffmann-La Roche Ltd
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Pfizer Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Alnylam Pharmaceuticals, Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Onyx Pharmaceuticals, Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Liver Cancer Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is expected to grow at a CAGR of 11.80% during the forecast period of 2023-2031.
The market is driven by the growing prevalence of liver cancer among people, especially the ageing population, around the world and the simultaneously rising demand for cancer therapeutics.
The increasing investment by market players and the government to introduce innovative solutions in the market and the rising demand for targeted therapy for cancer treatment can aid the market development.
The regional markets include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The types of liver cancers found in people include hepatocellular carcinoma, cholangio carcinoma, and hepatoblastoma, among others.
The market provides various therapy types including ablation therapy, embolization therapy, radiation therapy, targeted therapy, immunotherapy, and chemotherapy.
The different services available in the market include oral and intravenous administration.
The different distribution channels available in the market include hospital pharmacies, retail pharmacies, and online pharmacies.
The key players in the market include Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Exelixis, Inc., Merck & Co., Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER